CCI Closes Abuse of Dominance Case Against Batra Hospital, Rejects DG's Pricing Methodology
The Competition Commission found the Director General's comparisons of hospital prices with standalone diagnostic labs and procurement costs inadequate to establish unfair pricing under Section 4 of the Competition Act, 2002.
The Competition Commission of India, in an order dated 21 May 2026, closed the abuse of dominance proceedings against Batra Hospital & Medical Research Centre of Ch. Aishi Ram Batra Public Charitable Trust, New Delhi. The Commission, comprising Chairperson Ms. Ravneet Kaur and Members Mr. Anil Agrawal, Ms. Sweta Kakkad, and Mr. Deepak Anurag, found that the Director General's supplementary investigation report did not establish, on the evidence gathered, that Batra Hospital had charged unfair prices for room rent, medical tests, medical devices, consumables, or medicines in contravention of Section 4 of the Competition Act, 2002. The Commission held that neither of the two tests laid down in the United Brands case was satisfied on any count. The matter, which originated in 2015 from a complaint about disposable syringe pricing at a Delhi hospital, had by this stage expanded into a sector-wide inquiry covering twelve private super-specialty hospitals in Delhi.
How a Syringe Complaint Became a Sector-Wide Hospital Inquiry
The information in Case No. 77 of 2015 was filed by Shri Vivek Sharma under Section 19(1)(a) of the Competition Act against Becton Dickinson India (P) Ltd. and Max Super Specialty Hospital, Patparganj, Delhi. The allegation was that Becton Dickinson, a manufacturer of disposable syringes, in collusion with Max Patparganj, had deliberately printed a higher Maximum Retail Price on syringes sold at the hospital's in-house pharmacy compared to the MRP on the same product sold in the open market.
The Commission formed a prima facie view of contravention of Section 4 and directed the Director General to investigate. The DG's initial report found no exclusive agreement between Becton Dickinson and Max Patparganj and no contravention of Section 3(3). The Commission confirmed that finding. However, the DG had also found that Max Patparganj was earning significant profit margins on syringe sales and was compelling in-patients to purchase products only from its in-house pharmacy — conduct the DG characterised as contravening Section 4(2)(a)(ii).
In its order of 31 August 2018, the Commission observed that the DG had referenced conduct “akin to aftermarket abuse” without analysing it in sufficient depth. It directed a supplementary investigation, asking the DG to revisit the relevant market definition through the lens of aftermarket abuse, broaden the scope to all aftermarket healthcare products and services supplied to in-patients across Delhi's super-specialty hospitals, and consider Delhi as the relevant geographic market.
The supplementary investigation, submitted in confidential version on 24 December 2021, covered twelve super-specialty hospitals in Delhi. The DG defined twelve separate relevant markets — one per hospital — as the “market for provision of healthcare services/facilities for in-patients admitted to the respective private super specialty hospital” in Delhi. It found all twelve hospitals dominant in their respective markets and found contravention of Section 4 by each of them across five parameters: room rent, medical tests, medical devices, consumables, and medicines, for the period 2015 to 2018.
On 11 January 2022, the Commission deleted Becton Dickinson from the array of opposite parties, having found no contravention against it, and impleaded the eleven other hospitals as opposite parties alongside Max Patparganj. The Commission also directed that the matter be treated as twelve separate sub-cases, with separate investigation reports and separate hearings for each hospital. By order dated 21 May 2026, the Commission formally assigned the sub-case number 77(11) of 2015 to the proceedings against Batra Hospital.
Batra Hospital's Objections to the Supplementary Investigation
Batra Hospital raised several objections to the supplementary investigation report in written and oral submissions.
On relevant market, the hospital argued that the DG's definition — “market for provision of healthcare services/facilities for in-patients admitted to Batra Hospital in Delhi” — omitted the word “aftermarket”, thereby bringing within its scope services where patients had a genuine choice before admission, such as room rent and elective procedures. The hospital contended that room rent, stents, and knee and hip implant packages were not aftermarket services for locked-in patients and fell outside the scope of the Commission's 2018 direction.
On the restriction of the inquiry to twelve out of seventy hospitals, the hospital argued that if each hospital constitutes its own relevant market, the size or turnover of a hospital is irrelevant to whether it can abuse its dominant position over its own locked-in patients. Restricting the investigation to twelve hospitals on the basis of number of doctors, paramedics, and turnover, without Commission approval, amounted to exonerating the remaining fifty-eight hospitals without investigation.
On medical tests, the hospital submitted that comparing prices charged by a super-specialty hospital with those of standalone diagnostic laboratories such as Dr. Lal Path Labs was inappropriate. Diagnostic labs operate at larger scale with lower overhead costs and do not provide round-the-clock, time-critical services essential for admitted patients. The hospital also pointed out that a significant proportion of certain tests were conducted on out-patients who were not locked in.
On consumables and medicines, the hospital argued that the DG's methodology of comparing procurement prices with selling prices to derive profit margins was flawed because procurement price does not account for overhead expenses including storage, supply chain management, and inventory costs. The hospital also noted that consumables and medicines were sold at or below MRP, and that there is no legal obligation on any hospital to pass on procurement discounts to patients.
On the use of bills from Apollo Hospital and Ganga Ram Hospital to generate the list of top consumables and medicines investigated at Batra Hospital, the hospital submitted that if each hospital is a separate relevant market, the correct methodology would have been to analyse the top bills of Batra Hospital itself.
The Commission's Analysis: Relevant Market and Aftermarket
The Commission accepted that Batra Hospital is an “enterprise” within Section 2(h) of the Act, being engaged in providing healthcare services in exchange for monetary consideration.
On the relevant market question, the Commission examined whether the primary market for healthcare services and the secondary market for post-operative products and services supplied to in-patients constitute two separate markets or a unified systems market. It identified three conditions relevant to this determination: whether customers engage in whole-life costing; whether reputation effects deter the provider from setting supra-competitive prices in the secondary market; and whether the cost of switching from the primary product is low enough to discipline secondary market pricing.
The Commission observed that patients opting for elective treatment typically ascertain the overall cost of the procedure before admission, including medical consumables, medicines, tests, room rent, and doctor visit charges. Hospitals provide an all-inclusive estimated cost before admission. At that stage, patients are free to accept or reject the estimate, seek a second opinion, or choose a different hospital. The Commission found that patients are generally aware of costs before committing to treatment and are free to choose any hospital.
The Commission drew a distinction between in-patients admitted for elective treatment and those admitted for emergency or critical care. It focused the analysis on whether Batra Hospital had abused its dominant position by mandating in-patients admitted for elective treatment to use in-house medical products and services.
Why the DG's Findings on Each Parameter Did Not Survive Scrutiny
On room rent, the Commission found that comparing hospital room charges with rates at three-star and four-star hotels was not an appropriate benchmark. The Commission held that room rent charges would qualify as unfair only if they were significantly higher than those charged by other hospitals for comparable services, and that the DG's comparison with hotel rates did not establish this.
On medical tests, the Commission found the comparison of rates charged by Batra Hospital with those of a single standalone diagnostic lab each for X-rays, MRIs, and ultrasounds to be inadequate. It accepted that a hospital providing a twenty-four-hour functional testing facility with available staff and infrastructure to support faster turnaround times would have higher operating costs than a standalone lab. The Commission held that charges for X-ray and ultrasound procedures would qualify as unfair only where significantly higher than those charged by other hospitals for comparable services.
On medical devices, the Commission's finding was that the DG's analysis did not sustain a finding of unfair pricing.
On consumables and medicines, the Commission held that comparing procurement prices with selling prices to derive profit margins was not a relevant or appropriate methodology, because procurement price does not cover overhead expenses. The Commission also noted that there was no finding in the supplementary investigation report that prices charged for any consumable or medicine exceeded the MRP fixed by the manufacturer. It further observed that there is no obligation under any law upon any hospital to pass on procurement profits to patients. The sample size taken by the DG was also described as quite limited.
Outcome
The Commission held that neither of the two tests from United Brands was established on any count from the evidence gathered in the supplementary investigation. It found that no case of abuse of dominant position in contravention of Section 4 of the Act could be made out against Batra Hospital on the material and evidence available on record.
Case No. 77(11) of 2015 was directed to be closed. Pending interlocutory applications, if any, were also disposed of. The Commission granted confidentiality to documents, data, and information filed by the opposite party under Regulation 35 of the General Regulations, 2009 (as amended), in terms of Regulation 36 of the General Regulations 2024, read with Section 57 of the Act, for a period of three years from the date of the order. The Secretary was directed to communicate a certified copy of the order to Batra Hospital.